Bank of Hawaii Has $492,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Bank of Hawaii lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 33.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,334 shares of the medical device company’s stock after selling 3,666 shares during the period. Bank of Hawaii’s holdings in DexCom were worth $492,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in DXCM. Taylor Frigon Capital Management LLC increased its position in DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management bought a new position in DexCom during the third quarter worth $683,000. National Pension Service lifted its holdings in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares during the period. Intact Investment Management Inc. bought a new stake in DexCom during the third quarter valued at $650,000. Finally, Waters Parkerson & CO. LLC grew its holdings in DexCom by 4.2% during the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after acquiring an additional 10,892 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Wells Fargo & Company raised their price objective on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

DXCM opened at $77.83 on Tuesday. The firm’s fifty day moving average price is $70.76 and its two-hundred day moving average price is $88.93. The company has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a P/E/G ratio of 2.23 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,431 shares of company stock valued at $399,319. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.